Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366400 | 0.91 | KMT2A (0.40) | TK1KMT2ACYP1A2GRIA1GRIA2 | |
| SCHEMBL2684991 | 0.90 | TYMP (0.38) | TK1KMT2ACYP1A2GRIA1GRIA2 | |
| SCHEMBL5199542 | 0.84 | TK1 (0.39) | TK1TK2 | |
| SCHEMBL8150170 | 0.84 | TK1 (0.41) | TK1KMT2AHPGDTK2 | |
| SCHEMBL6924149 | 0.83 | TK1 (0.39) | TK1KMT2ACYP1A2GRIA1GRIA2 | |
| SCHEMBL6931042 | 0.83 | TK1 (0.39) | TK1KMT2ACYP1A2GRIA1GRIA2 | |
| SCHEMBL2153216 | 0.82 | LMNA (0.44) | TK1KMT2ATK2 | |
| SCHEMBL8135550 | 0.82 | TK1 (0.37) | TK1KMT2ACYP1A2GRIA1GRIA2 | |
| SCHEMBL5370203 | 0.81 | TYMP (0.35) | TK1HPGDTK2 | |
| SCHEMBL6468180 | 0.81 | TK1 (0.37) | TK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050260131-A1 | Pharmaceuticals for enhanced delivery to disease targets | GENERAL ELECTRIC COMPANY | 2005-11-24 | — | — | US | disclosed |
| US-6548651-B1 | Conjugating cationic peptides to peptide nucleic acids; microbiocides | PANTHECO A/S (DK) | 2003-04-15 | — | — | US | disclosed |
| EP-0804456-B1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2000002864-A1 | PRECUSORS FOR PNA-MONOMERS | MARTENS JUERGEN (DE) | 2000-01-20 | — | — | WO | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260131-A1 | Pharmaceuticals for enhanced delivery to disease targets | DNPEP, IAPP, PCSK9 | TK1 820/4885KMT2A 4356/4885CYP1A2 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.